Biomedical Physics Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Clin Cancer Res. 2009 Dec 1;15(23):7352-60. doi: 10.1158/1078-0432.CCR-09-0960. Epub 2009 Nov 17.
Mitochondria and ionizing radiation overlap in a number of features; for instance, both generate harmful reactive oxygen species, and that radiation can induce cell death through the intermediary of mitochondria. Because a number of genetic variations in nuclear genes are frequently associated with response to cancer treatment, the aim of this case-control study was to test the hypothesis that mitochondrial DNA (mtDNA) genetic variations can contribute to patient-to-patient variability in normal tissue response to radiotherapy.
Thirty-two nasopharyngeal carcinomas patients treated with definitive radiotherapy were included. The grade (G) of s.c. and deep tissue fibrosis was scored according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer grading system. Coding and RNA mtDNA (between 611 and 15,978 bp) were sequenced, and genetic variations were scored. Mitochondrial respiratory activity was measured by resazurin reduction assay.
Data showed a significantly (P = 0.003) higher number of nonsynonymous genetic variations in the radiosensitive (G(2)-G(3); 16 patients) as compared with the control (G(0)-G(1); 16 patients) groups. The nonsynonymous A10398G variation in the ND3 gene was significantly associated with fibrotic reaction (P = 0.01). The radiosensitive patients had a 7-fold (95% confidence interval, 1.16-51.65) higher risk of developing moderate to severe fibrosis (G(2)-G(3)) following radiotherapy. This was significantly correlated with lower mitochondrial respiratory activity (P = 0.001).
Mitochondria contribute to radiation sensitivity, and genetic variations can be associated with late reactions to radiotherapy. Predictive markers of radiosensitivity should take into account mtDNA genetic variations in addition to variations in nuclear genes.
线粒体和电离辐射在许多方面存在重叠;例如,两者都会产生有害的活性氧物种,而且辐射可以通过线粒体的中介诱导细胞死亡。由于核基因中的许多遗传变异经常与癌症治疗反应相关,因此本病例对照研究的目的是检验假设,即线粒体 DNA(mtDNA)遗传变异可以导致患者对放射治疗的正常组织反应的个体间变异性。
纳入了 32 例接受根治性放疗的鼻咽癌患者。根据放射治疗肿瘤学组/欧洲癌症研究与治疗组织的分级系统,对皮下和深部组织纤维化的程度(G)进行评分。对编码和 RNA mtDNA(611 至 15978bp 之间)进行测序,并对遗传变异进行评分。通过 Resazurin 还原测定法测量线粒体呼吸活性。
数据显示,在放射敏感组(G2-G3,16 例患者)中,非同义遗传变异的数量明显高于对照组(G0-G1,16 例患者)(P=0.003)。ND3 基因中的非同义 A10398G 变异与纤维化反应显著相关(P=0.01)。放射敏感组患者在接受放疗后发生中度至重度纤维化(G2-G3)的风险高 7 倍(95%置信区间,1.16-51.65)。这与较低的线粒体呼吸活性显著相关(P=0.001)。
线粒体有助于放射敏感性,遗传变异与放疗后的晚期反应有关。放射敏感性的预测标志物除了核基因的变异外,还应考虑 mtDNA 遗传变异。